Myeloablative Busulfan, Fludarabine and Melphalan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Childhood Myeloid Malignancy
Asia-Pacific Journal of Clinical Oncology · 19.04.2026
DOI: 10.1111/ajco.70113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, online erschienen am 19.04.2026. Verfasst von Mayank Dhamija und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Haematology, Oncology, Blood and Marrow Transplantation, Perth Children's Hospital, Perth, Western Australia, Australia. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Health and Medical Research Council of Australia.
Abstract (Originalsprache)
Background
Allogeneic hematopoietic stem cell transplant (HSCT) is a proven curative therapy for children with high‐risk myeloid malignancies. Disease relapse, transplant‐related mortality and graft versus host disease (GvHD) are the main causes of treatment failure and death post‐transplant. The optimum pretransplant conditioning regimen is yet to be defined. There is limited data regarding the use of busulfan, fludarabine and melphalan as a myeloablative conditioning regimen in children receiving HSCT for myeloid malignancies.
Aim
To evaluate the outcome of pharmacokinetic‐guided busulfan dosing, in addition to fludarabine and melphalan, as a myeloablative conditioning regimen in children with myeloid malignancies.
Methods
We conducted a retrospective, single‐center study of all patients
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Haematology, Oncology, Blood and Marrow Transplantation, Perth Children's Hospital, Perth, Western Australia, Australia.
- Medical Affairs, Hematology Oncology, ICON Biotech, ICON Plc, Dublin, Ireland.
- Pharmacy Department, Perth Children's Hospital, Perth, Western Australia, Australia.
- Leukaemia Translational Research Laboratory, WA Kids Cancer Centre, The Kids Research Institute Australia, Perth, Western Australia, Australia.
- Curtin Medical School, Curtin University, Perth, Western Australia, Australia.
- Curtin Medical Research Institute, Curtin University, Perth, Western Australia, Australia.
ORCID-Profile: Mayank Dhamija, Johnathan Soggee, Laurence C Cheung, Rishi S Kotecha, Shanti Ramachandran
Förderung
- National Health and Medical Research Council of Australia
Zitieren
APA
Dhamija, M., Kerr, F., Gough, H., Soggee, J., Cheung, L. C., Kotecha, R. S., & Ramachandran, S. (2026). Myeloablative Busulfan, Fludarabine and Melphalan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Childhood Myeloid Malignancy. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.70113
Vancouver
Dhamija M, Kerr F, Gough H, Soggee J, Cheung LC, Kotecha RS, et al. Myeloablative Busulfan, Fludarabine and Melphalan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Childhood Myeloid Malignancy. Asia-Pacific Journal of Clinical Oncology. 2026. doi:10.1111/ajco.70113
BibTeX
@article{Dhamija2026,
author = {Dhamija, Mayank and Kerr, Fiona and Gough, Hazel and Soggee, Johnathan and Cheung, Laurence C and Kotecha, Rishi S and Ramachandran, Shanti},
title = {Myeloablative Busulfan, Fludarabine and Melphalan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Childhood Myeloid Malignancy},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
doi = {10.1111/ajco.70113}
}
EUVIMED